Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FABP1 | P07148 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787514 | 0.90 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1GAATSHRGFER | |
| SCHEMBL5242720 | 0.87 | ALDH1A1 (0.67) | L3MBTL1ALDH1A1GAATSHRALOX15 | |
| SCHEMBL5244216 | 0.87 | KMT2A (0.47) | L3MBTL1ALDH1A1MAPK1KMT2APKM | |
| SCHEMBL4786255 | 0.86 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1TSHRGFERALOX15 | |
| SCHEMBL5242949 | 0.86 | ALDH1A1 (0.53) | L3MBTL1ALDH1A1GAATSHRGFER | |
| SCHEMBL4784036 | 0.85 | TSHR (0.67) | L3MBTL1ALDH1A1GAATSHRGFER | |
| SCHEMBL4787536 | 0.85 | ALDH1A1 (0.55) | L3MBTL1ALDH1A1GAATSHRALOX15 | |
| SCHEMBL4785121 | 0.84 | TSHR (0.54) | L3MBTL1ALDH1A1GAATSHRGFER | |
| SCHEMBL5244384 | 0.82 | HSD11B1 (0.49) | L3MBTL1ALDH1A1GAAALOX15FABP1 | |
| SCHEMBL4788589 | 0.82 | PKLR (0.45) | L3MBTL1ALDH1A1GAAMAPK1FABP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | L3MBTL1 2603/4885ALDH1A1 2627/4885GAA 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.